Skip to main content

ESTUDIO DE LOS PROCESOS DE INMUNOTROMBOSIS Y LIPOTOXICIDAD COMO MECANISMOS DE PATOGENESIS EN LA ENFERMEDAD DE CHAGAS.

PI18/01054

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA (ISGLOBAL)
Execution centre FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA (ISGLOBAL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds

  • Martinez-Peinado, Nieves|||0000-0001-7107-5374
  • Cortés Serra, Núria|||0000-0001-5396-3757
  • Sherman, Julian
  • Rodriguez, Ana|||0000-0002-0060-3405
  • Gascon, Joaquim|||0000-0002-5045-1585
  • Alberola, Jordi|||0000-0002-1033-6339
  • Pinazo, Maria-Jesus|||0000-0002-4237-1075
  • Rodriguez-Cortes, Alheli|||0000-0003-3617-0119
  • Alonso Padilla, Julio|||0000-0003-4466-7969
  • Martori Muntsant, Clara|||0000-0002-7872-918X
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and affects over 6 million people worldwide. Development of new drugs to treat this disease remains a priority since those currently available have variable efficacy and frequent adverse effects, especially during the long regimens required for treating the chronic stage of the disease. T. cruzi modulates the host cell-metabolism to accommodate the cell cytosol into a favorable growth environment and acquire nutrients for its multiplication. In this study we evaluated the specific anti-T. cruzi activity of nine bio-energetic modulator compounds. Notably, we identified that 17-DMAG, which targets the ATP-binding site of heat shock protein 90 (Hsp90), has a very high (sub-micromolar range) selective inhibition of the parasite growth. This inhibitory effect was also highly potent (IC50 = 0.27 μmol L-1) against the amastigote intracellular replicative stage of the parasite. Moreover, molecular docking results suggest that 17-DMAG may bind T. cruzi Hsp90 homologue Hsp83 with good affinity. Evaluation in a mouse model of chronic T. cruzi infection did not show parasite growth inhibition, highlighting the difficulties encountered when going from in vitro assays onto preclinical drug developmental stages.